Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Antengene Corporation Limited ( (HK:6996) ) is now available.
Antengene Corporation Limited, a biopharmaceutical company specializing in oncology therapies, reported steady revenue growth driven primarily by accelerated contributions from Mainland China and strengthened commercialization partnerships. The company continues to streamline operations, achieving lower selling, distribution, and administrative expenses through improved promotional and operational efficiency, while maintaining a focus on clinical research and early-stage R&D.
For the year ended December 31, 2025, revenue rose 14.5% year-on-year to RMB105.3 million, while total loss narrowed to RMB239.1 million on the back of sharply reduced R&D and administrative costs. Adjusted loss excluding net foreign exchange differences decreased by 33.7% to RMB201.5 million, underscoring enhanced cost control and efficiency measures that are gradually improving Antengene’s financial profile despite ongoing losses.
The most recent analyst rating on (HK:6996) stock is a Sell with a HK$3.00 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.
More about Antengene Corporation Limited
Antengene Corporation Limited is a biopharmaceutical company focused on innovative oncology therapies, with a commercial presence in Mainland China and partnerships aimed at deepening market penetration. The group derives revenue from the commercialization of its cancer treatments and continues to balance R&D investment with efforts to improve operational and promotional efficiency across its core markets.
Average Trading Volume: 3,389,181
Technical Sentiment Signal: Sell
Current Market Cap: HK$2.57B
Learn more about 6996 stock on TipRanks’ Stock Analysis page.